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Abstract 
Background: Drug injection is considered an important issue for the public health of the Republic of Moldova. In the RM the intravenous drug users 
(IVDU) are the key population for HIV infection, B and C hepatitis, TB and sexual transmitted diseases. The aim of the study was to assess the tuberculosis 
evolution and treatment outcome in intravenous drug addicted patients.
Material and methods: A retrospective selective, descriptive study targeting socioeconomic, demographic, economic and epidemiological peculiarities, 
case-management, diagnosis of radiological aspects and microbiological characteristics of 233 patients with pulmonary tuberculosis registered in Chisinau 
city from 2012 to 2016 among them 48 IVDU was performed. The results were compared with a sample of 34 IVDU.
Results: Men were predisposed for drug addiction and the age is younger in addicts with tuberculosis. Socioeconomic vulnerability is extended in the 
selected groups; however, the poverty deepness was more important in addicted patients with tuberculosis. Close contact with a sick patient predominated 
in addicts with tuberculosis, but nobody assessed the contact in addicts without tuberculosis. Associated diseases predominated in addicts with or without 
tuberculosis, more frequently were: HIV infected individuals, viral hepatitis and neurological disorders.
Conclusions: Risk factors for tuberculosis in drug addicts were: unemployment and associated lack of health insurance, patient’s homeless state, middle 
adulthood and the immune suppressive condition – HIV infection. Major disease-related characteristic in IVDU patients was the presence of severe 
destructive forms of tuberculosis and "loss to follow-up" as outcome.
Key words: tuberculosis, drug use, addiction, risk factors.
Introduction
Drug use has important criminal and social implication 
in the Republic of Moldova (RM) [14, 17, 21, 23, 30, 31]. 
According to the national epidemiological data in 2009 on 
the left side of the territory of the RM were diagnosed 1333 
new cases of drug users, among them 6.5% were women. 
The RM is an agrarian country and the production of the 
vegetable drugs from poppy and hemp raw material is af-
fordable [31]. Despite this, the prices for opium, marijuana, 
heroin, cocaine and other drug extracts is continuously in-
creasing. The total number of drug-related crimes during 
the period 2008-2010 decreased (2008-2103 crimes, 2009-
1865 crimes, 2015-745 crimes), but the number of crimes 
related to the narcotics trade constituted only 15% [12]. So, 
it can be deducted that most of the trials are related against 
drug users and not against the drug trafficking. [31] The de-
velopment of new narcotic and new generation psychotro-
pic substances has serious health consequences. The preva-
lence of HIV infection among Moldovan intravenous drug 
users (IVDU) reached 21.0% in 2008 [3]. The globalization 
of the illicit drug use determined the development and im-
provement of the legislative basis for preventing consump-
tion, combating illicit drug trafficking, also counseling and 
treatment of the drug addiction [27, 28, 35]. An important 
step in the prevention of the consumption and combating 
drug trafficking was the approval of the National Anti-drug 
Strategy for 2011-2018 [12]. The strategy was developed ac-
cording to the European Anti-drug Strategy, Convention on 
Narcotic Drugs, Convention against Illicit Traffic of Narco-
tic Drugs and Psychotropic Substances, Declaration about 
the Principles on the Drug Demand Reduction [27, 28]. The 
implementation of the Strategy among young IVDU dimin-
ished the rate of died people due to the overdoses from 131 
in 2002, to 8 in 2008 and 12 in 2009. However, the rate of 
IVDU with HIV infection reached 8.5%, with viral hepati-
tis – 9.1%, with TB 1.24% and sexual transmitted infection 
12.7% in 2013 [17]. The IVDU have various barriers in the 
accessing health care and getting an effective treatment for 
their addictive conditions and associated diseases [9]. High 
degree of stigma and social marginalization contribute to 
the lack of the short-term residential treatment, therapeutic 
communities and rehabilitation services [34]. Due to highly 
repressive policies the IVDU are frequently incarcerated 
[31]. Prisons represent an extensive infectious reservoir [8, 
29]. Specific needs of the key population IVDU are underes-
timated contributing to gaps in management of the diagno-
sis and treatment of tuberculosis [5, 35]. In several high tu-
berculosis countries the systematic screening of drug users 
through the chest X-ray and interferon-gamma assay is an 
important action in the control of the disease at the national 
level [7, 10, 13, 18].
Tuberculosis represents one of the 10 leading causes of 
death globally, according to the WHO Global Tuberculosis 
Report [40]. After the Millennium Summit, that was held 
in 2000, the 191 member states of the United Nations Or-
ganization adopted the 8 Millennium Development Goals 
(MDGs), which targeted the main directions of global ef-
forts [32]. A major influence obtained the activities for 
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reduction of extreme poverty (Objective 1), fighting HIV/
AIDS, malaria and tuberculosis (objective 6). Despite of 
important progress in obtaining the results, on 15 Septem-
ber 2015 there were adopted new 16 objectives: Sustainable 
Development Goals (SDGs), oriented to the poverty alle-
viation, reducing inequalities, good health, well-being, and 
other objectives to be realized in the next 15 years [33].  The 
comprehensive approach to tuberculosis was identified in 
several objectives: to put an end to poverty and hunger, fight 
HIV/SIDA, malaria and tuberculosis, to provide sustainable 
development of communities (target – treatment support 
of patients with HIV/AIDS, tuberculosis, etc.).  It demon-
strated the importance of activities implemented to combat 
the poverty-related diseases and contributing conditions, 
one of them – the drug use [38]. As an immediate feedback 
to SDGs World Health Organization adopted the End TB 
Strategy in 2014 that targets the decrease with 90% of death 
cases due to tuberculosis and decrease with  80% incidence 
till 2030, comparing with 2015 [37]. The last WHO report 
estimated the RM remains one of the highest burdened 
countries by drug resistant tuberculosis with an estimated 
rate of 26% among new cases and 56% among previously 
treated cases [43]. The social determinants of tuberculosis 
were well recognized [39, 40, 41]. It was identified a strong 
relationship between social vulnerability and psychotropic 
substance abuse: tobacco smoking, alcohol abuse and drug 
use. [39] Addiction is a compulsive need for use of a habit-
forming substance (nicotine, alcohol, or heroine) character-
ized by tolerance and well-defined symptoms upon with-
drawal [9, 21, 39]. From the physiopathology point of view, 
addiction affects neurotransmission and interactions within 
reward structures of the brain, including the nucleus accum-
bens, anterior cingulate cortex, basal forebrain and amyg-
dale. It affects neurotransmission and interactions between 
cortical and hippocampus circuits and brain reward struc-
tures, such as the memory of previous exposures to rewards 
(ex. alcohol, drugs, nicotine, food, sex). It leads to a biologi-
cal and behavioral response to external triggers which en-
gage the person in addictive behaviors. The frontal cortex 
of the brain and underlying white matter connections are 
fundamental in the manifestations of altered impulse con-
trol, judgment, and the dysfunctional pursuit of rewards. 
The frontal lobes are important in inhibiting impulsivity 
and in assisting individuals to appropriately delay gratifica-
tion. Frontal lobe morphology, connectivity and function-
ing are still in the process of maturation during adolescence 
and young adulthood. The early exposure to substance use 
of a young person is a significant factor in the development 
of addiction. Addiction is characterized by: 1. inability to 
consistently abstain; 2. impairment in behavioral control; 3. 
craving or increased “hunger” for nicotine, alcohol, drugs 
or rewarding experiences; 4. diminished recognition of sig-
nificant problems and interpersonal relationships; 5. dys-
functional emotional response. During addiction there is 
a significant impairment in executive functioning [35]. It 
manifests in problems with perception, learning, impulse 
control, compulsivity, and judgment. People with addiction 
often manifest a lower readiness to change their behaviors. 
The developing of frontal lobes of adolescents and young 
adults may contribute to disturbance of executive function-
ing and predispose young people to engage in “high risk” 
behaviors, including engaging in smoking, alcohol or other 
drug use. Addiction is more than a behavioral disorder. 
Features of addiction include aspects of a person’s cogni-
tions, emotions, and interactions with others. It consists in 
period of relapse and remission. Clinical interventions are 
difficult to perform and are quite ineffective. Close moni-
toring of the behaviors of the individual and contingency 
management can contribute to positive clinical outcomes. 
The engagement in health promotion activities which un-
derline personal responsibility and accountability, connec-
tion with others, and personal growth also contribute to the 
patient’s recovery. It is important to note that addiction can 
cause disability or premature death, especially when is left 
untreated or is treated inadequately. Self-management with 
mutual support and professional care provided by trained 
staff is very important in the person’s recovery from addic-
tion [19, 21, 35].  Drug addiction is a chronic brain disease 
that causes the compulsive behavior to seek and use the 
substances. The addiction changes the decision-making ca-
pacity of the person and it should be treated like any other 
illness. Withdrawal syndrome is a pathological condition 
directly related to addiction, which occurs when the addict-
ed consumer drops the doses. If dependence is strong, the 
withdrawal can manifest violent: hypertension, palpitations, 
deep sweating, muscle pain, joint pain, headache, vertigo, 
vomiting, psychomotor excitation, convulsions, anxiety, in-
somnia, psychological and physical discomfort. Methadone 
is a synthetic opioid with pharmacological effects similar to 
morphine products. Methadone is bioavailable consumed 
by oral or injected way. The main effect of methadone is 
expressed by receptors and is similar to that produced by 
endogenous opiates such as encephaline and endorphin. 
Methadone increases the elimination of neuromediators: 
acetylcholine, noradrenaline and dopamine. Methadone de-
creases the desire to use heroin and other opiates, eliminates 
the symptoms of the withdrawal and blocks the euphoric 
effects of other drugs or substances [21].
Genetic factors account one half of the likelihood that 
an individual will develop drug addiction. However the 
interaction of the environmental factors increases the pre-
disposition for addiction. Culture also plays an important 
role for increasing the possibility that the persons with 
biological vulnerabilities develop addictions. Other factors 
that contribute to the appearance of addiction, leading to 
its characteristic bio-psycho-socio-spiritual manifestations 
are: 1. Biological failure in the function of reward circuits; 2. 
Repeated engagement in drug use or other addictive behav-
iors (alcohol, tobacco smoking), causing neuro-adaptation 
and engagement in addictive behaviors; 3 Cognitive and 
affective distortions, which impair perceptions and fail the 
ability to deal with feelings, resulting in significant self-de-
ception; 4. Disruption from the healthy social supports; 5. 
Appearance of the problems in interpersonal relationships 
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which impact the development of addictive behavior; 6. Ex-
posure to trauma or stress that determines an individual’s 
coping abilities; 6. Distortion in meaning, purpose and val-
ues that establish attitudes, thinking and behavior; 7. distor-
tions in the connection with person’s self and community; 8. 
Co-morbid psychiatric disorders in persons who engage in 
substance use or other addictive behaviors [5, 36].
The socioeconomic and political crisis through which 
passes the RM determines the increasing of the social vul-
nerable population, among which the addictive habits are 
very frequent [3, 23, 30, 31]. The health-related risks in 
addicts are highly expressed. It was established a 55 times 
higher risk to develop tuberculosis among persons with 
alcohol use disorders, 10 times higher risk to develop tu-
berculosis among tobacco smokers and non-estimated high 
risk in IVDU population. The susceptibility for tuberculosis 
is determined by: 1. The social mixing patterns of addicts; 
2. Weak immune system due to associated conditions (mal-
nutrition, HIV-infection, gastro-intestinal disorders, etc.) 
leading to reactivation of the latent TB infection; 3. Toxic 
effects of drugs on different organs; 4. Micro- and macronu-
trient deficiency. 
So, the aim of the study was to assess the tuberculosis 
features and treatment outcome in the intravenous drug ad-
dicted patients. 
Objectives were: 1. Assessment of the tuberculosis exten-
sion among the population of the IVDU from the Republic 
of Moldova and its epidemiological evolution; 2. Assess-
ment of general, socioeconomic and epidemiological risk 
factors of IVDU with tuberculosis and comparing with two 
control samples of IVDU and pulmonary tuberculosis; 3. 
Evaluation of the case-management, diagnosis, radiological 
aspects and microbiological characteristics of IVDU with 
tuberculosis comparing with a control sample of pulmonary 
tuberculosis; 4. Assessment of the specialized health care ac-
cessibility of the IVDU with tuberculosis comparing with 
the control sample of pulmonary tuberculosis.
Material and methods
It was performed a retrospective selective, descriptive 
study targeting social, demographic, economic and epide-
miological peculiarities, case-management, diagnosis, ra-
diological aspects and microbiological characteristics of 233 
patients with pulmonary tuberculosis registered in Chisinau 
during the period 2012 to 2016. Among them, 48 were es-
tablished being IVDU and 185 patients had no drug addic-
tion. The results were compared with a sample of 34 IVDU 
without tuberculosis or a history of a previous treatment 
for tuberculosis. The electronic system for monitoring and 
follow-up of tuberculosis cases (SIME TB) was used for the 
selection. Data were extracted from the statistic templates 
F089/1-e “Declaration about patient’s established diagnosis 
of new case/relapse of active tuberculosis and restart of the 
treatment and its outcomes” and F090/e “Declaration and 
follow up of multidrug-resistant tuberculosis”. Inclusion 
criteria in the study group (SG): age more than 18 years 
old, tuberculosis and associated intravenous drug addic-
tion, signed informed consent allowed the selection of 48 
patients. In the 1st control group (1st CG) were selected 185 
new diagnosed cases with pulmonary tuberculosis without 
associated drug addiction, also in the past. Assessing the 
type of the drug addiction it was established that 45 (93.7%) 
of the IVDU from the SG had mental illness and behavior 
disorders due to the opioid use and 3 (6.3%) had mental 
illness and behavior disorders  due to multiple drug use of 
psychoactive substances. In the 2nd CG 14 (41.2%) patients 
had mental illness and behavior disorders due to the opioid 
drug use, 16 (47.1%) had mental illness and behavior dis-
orders due to multiple drug use of psychoactive substances 
and 4 (11.7%) patients had mental illness and behavior dis-
orders due to the non-opioid substances use. Most of pa-
tients, 21 (61.7%) cases, were previously treated. Each sec-
ond patient had a relapse – 10 (47.7%), 3 (14.3%) were after 
loss to follow-up, 7 (33.3%) had methadone addiction and 1 
(4.7%) required the preventive treatment. Each third patient 
from the 2nd CG, 12 (35.3%), was hospitalized for the first 
time for the treatment of the withdrawal syndrome. Each 
second patient of the 2nd SG (21 (61.7%) had more than 10 
years of drug use and the rest of the group had a shorter 
life history of addiction. Most of them, 26 (76.5%) cases, di-
rectly addressed to the narcological specialized institution 
and 8 (23.5%) patients by the third parts (relatives, police). 
Assessing the drug types, most of them – 14 (41.2%) used 
heroin, 10 (29.4%) a combination of drug with heroin and 
10 (29.4%) other types of drugs.
All patients with tuberculosis were investigated and 
treated according to the National Clinical Protocol 123 
“Tuberculosis in Adults” [22]. The “new case” was consid-
ered the patient never treated for TB or has taken anti-TB 
drugs less than one month. Previously treated were con-
sidered patients with relapse, treatment failure and loss to 
follow-up. For assessing the socioeconomic barriers and 
health care accessibility of the IVDU the 2nd control group 
(2nd CG) was selected and was composed of 34 patients. The 
investigational schedule included demographic, social and 
epidemiological data: sex (male/female ratio), age (distri-
bution in age groups), demographic characteristics (urban/
rural residence), educational level, socio-economic status 
(employed, unemployed, retired, disabled, student), health 
insurance status (lack of insurance), migration and deten-
tion history, presence of high risk (close contact with an 
infectious source, comorbidities, health care seeking behav-
ior, way of the patient’s detection). Enrolled patients from 
the SG were selected in the period 01.01.2012-31.12.2016. 
Patients from the 1st CG were enrolled during the period 
01.01.2015-31.12.2015. For patients from the 2nd CG the 
period of selection – during 01.01.2017-31.05.2018. The 
samples of patients with tuberculosis were managed in the 
frame of the clinical services of the Municipal Clinical Hos-
pital of Pneumophtisiology of Chisinau and the samples of 
IVDU were managed in the Republican Narcological Dis-
pensary of the Republic of Moldova. Statistic analysis was 
carried out using the quantitative and qualitative research 
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methods [24, 26]. Statistical survey was performed using 
Microsoft Excel XP soft.
Results
According to the data obtained from the monitoring and 
follow-up of cases system during the period 2011-2018 it 
was established an important fluctuation of registered tu-
berculosis among Moldovan drug users. In 2011 were reg-
istered 56 cases, 2012 – 48 cases, 2013 – 71 cases, 2014 – 70 
cases, 2015 – 43 cases, 2016 – 47 cases and in 2017 – 55 cases 
[2].  Distributing selected patients, according to the sex it 
was established the statistical predominance of men in all 
three groups, with the highest rate in the 2nd CG. So, men 
were 33 (97.1%) in the 2nd CG, 42 (87.5%) in the SG and 
138 (74.6%) in the 1st CG. The male/female ratio was 7/1 in 
the SG, 2.9/1 in the 2nd CG and 33/1 in the 1st CG. Men pre-
dominated statistically in the 2nd CG compared with the SG 
and the 1st CG. Repartition of the patients into age groups, 
according to the WHO recommendation identified that the 
largest subgroup in the SG was 35-44 years, followed by the 
25-34 years in the SG. In the 1st CG predominated the 35-44 
years group, followed in the same proportion of those with 
45-54 years and 25-34 years old. In the 2nd CG the majority 
of patients were between 25-34 years old and every third 
patient was between 35-44 years old. Comparing the groups 
was identified statistical predominance of the young group 
of 25-34 years old in the 2nd CG compared with the SG and 
the 1st CG, as well in the SG compared with the 1st CG. The 
middle adulthood group of 35-44 years old predominated 
in the SG compared with the 1st CG and the 2nd CG. Patients 
aged between 45-55 years old predominated in the 1st CG 
compared with the 2nd CG and the SG. Obtained data dem-
onstrated that the age for acquiring tuberculosis is younger 
in addicted patients than in those without drug addiction. 
The patients with tuberculosis had urban residence in two 
thirds of the groups (SG and 1st CG). The majority of the 
2nd CG had urban residence. The statistical predominance 
of the urban residence was identified in the 2nd CG com-
pared with the SG and the 1st CG. Homeless patients were in 
a similar proportion in both groups with tuberculosis (SG 
and the 1st CG) which statistically predominated compared 
with the 2nd CG (tab. 1). So, distributing patients accor-
ding to the biological characteristics it was argued that 
young IVDU men, from urban areas had high probability 
to get tuberculosis.
Distributing patients according to the economic status, it 
was established that employed persons, who are contributing 
to the health budget by paying taxes, health insurance policy 
and social taxes predominated in the 2nd CG compared with 
the study group. As to health insurance and social security 
more frequently had them patients from the same group. 
Unemployed patients statistically predominated in the SG 
Table 1
Distribution of patients by sex, age and demographic data
Indices
Sex
Age
Residence  
Study group
1st control 
group
2nd control 
group
N=48 (P%) N=185 (P%) N=34 (P %)
Sex Men 42 (87.5) * 138 (74.59) ●●● 33 (97.1)
Women 6 (12.5) * 47 (25.41)●●● 1 (2.9)
Age 
groups
18-24 years 0*** 24 (12.97) 3 (8.8)
25-34 years 20 (41.7) ** # 36 (19.46) ●●●  20 (58.8)
35-44 years 27 (56.2)*** # 52 (28.11) 10 (29.4)
45-55 years 1 (2.1) ** 42 (22.73) ●●● 1 (2.9)
>55 years 0*** 31 (16.4) ●●● 0
Resi-
dence 
Urban 35 (72.9) # 139 (75.13) ●●● 31 (91.2)
Rural 5 (10.2) ** 46 (24.86)●●● 3 (8.8)
Homeless 8 (16.7) # 29 (15.68) ●●● 0
Note: Applied statistical test: paired simple T-test, P – probability.
Statistically significant differences between: study group IVDU-TB 
compared to the 1st control group TB: * – p<0.05;** – p<0.01; *** – p<0.001; 
study group IVDU-TB compared to the 2nd control group TB: # p<0.05; 
## – p<0.01; ### – p<0.001; the 1st control group TB compared to the 2nd 
control group: ● – p<0.05; ●● – p<0.01; ●●● – p<0.001;
Table 2
Distribution according to the socioeconomic data
Indices Economic state
Study group 1st control group 2nd control group
N=48 (P%) N=185 (P%) N=34 (P%)
Economicaly stable Employed 2 (4.7) ## 25 (13.51) ●● 10 (29.4)
Insured 8 (16.7) ***### 46 (24.8) 12 (35.3)
Economicaly vulnerable Disease disabled 3 (6.3) 14 (7.57) 3 (11)
Retired 0 15 (8.11) 1 (2.9)
Students 0 7 (3.78) 0
Unemployed 43 (89.6) ***### 124 (67.03) 20 (58.8)
Lack of health insur-
ance
40 (83.3) *** ### 139 (75.13*) 22 (64.7)
Note: Applied statistical test: paired simple T-test, P – probability;
Statistically significant differences between: study group IVDU-TB compared to the 1st control group TB: * – p<0.05;** – p<0.01; *** – p<0.001; 
study group IVDU-TB compared to the 2nd control group TB: # p<0.05; ## – p<0.01; ### – p<0.001; the 1st control group TB compared to 
the 2nd control group: ● – p<0.05; ●● – p<0.01; ●●● – p<0.001;
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compared with the 1st CG and the 2nd CG. The same rate was 
established regarding the patients who lacked the health and 
social insurance. Despite the predominance of the disabled 
patients, retired and students in the 1st SG compared with 
other groups, the statistical significance was not achieved. 
So, the socioeconomic vulnerability was identified in all 
selected patients, but its deepness was more evident in the 
IVDU patients with tuberculosis (tab. 2).
Assessing the educational level, it was established that 
most of the patients from the SG and the 1st CG graduated 
upper secondary level of the education. The rate of patients 
with upper secondary level statistically predominated in the 
SG and the 1st CG compared with the 2nd CG. Primary and 
low secondary education statically predominated in the 2nd 
CG compared with the SG and 1st CG. Secondary technical 
vocational education predominated in the 1st CG compared 
with the SG and the 2nd CG, but the statistical difference was 
not achieved. Bachelor studies predominated in the 2nd CG 
but the statistical difference was not achieved either. Ex-
posed data are revealed in the table 3.
Hierarchy of risk groups, according to the widest rate 
of patients identified that the major social characteristics 
of patients from all three groups were the vulnerable eco-
nomic state and living in poor conditions. Extreme poverty, 
expressed by homelessness was identified only in the study 
group and the 1st CG. History of migration during the last 
year statistically predominated in the 1st CG compared with 
the SG and the 2nd CG. History of imprisonment statistically 
predominated in the SG compared with the 1st CG. Close in-
fectious contact, established as being a member of a family 
TB clusters statistically predominated in the SG compared 
with the 1st CG. There were no available data for the 2nd CG.
The review of comorbidities in 3 substances users estab-
lished a high prevalence of HIV infection, hepatitis C and 
sexual transmitted diseases in most of the researches [15, 
16, 29].
Table 4
Distribution according to the risk groups
Category Risks 
Study group 1st control group 2nd control group
N=48 (P%) N=185 (P%) N=34 (P %)
Socioeconomic Poverty 29 (60.4) 106 (57.29) ●●● 14 (41.2)
Homelessness 8 (16.7) ### 29 (15.68) ●●● 0
Migration 2 (4.2) 24 (12.97) ●●● 0
History of detention 16 (33.3) *** 2 (1.1) 7 (20.6)
Biological Close contact 15 (31.2) *** 15 (8.11) NA
Associated diseases 48 (100) *** 50 (27.03) ●●● 31 (91.2)
HIV-infection 21 (43.7) ***### 11 (5.94) 1 (2.9)
Chronic alcoholism 3 (6.2) *** 13 (7.03) ●●● 12 (35.2)
CRD 8 (16.7) 15 (8.2) 7 (20.6)
GID 10 (20.8) ### 4 (2.1) ●●● 28 (82.3)
Viral hepatitis 2 (4.6) # 2 (1.1) ●●● 8 (23.5)
Mental disorders (excluding IVDU) 1 (2.1) ### 4 (2.16) 31 (91.2)
Neoplasm 1 (2.1) 1 (0.5) 0
Renal diseases 4 (11.7)
Others 2 (4.6)
Note: Applied statistical test: paired simple T-test, P – probability; NA-non available, CRD-chronic respiratory diseases, GID-gastrointestinal diseases.
Statistically significant differences between: study group IVDU-TB compared to the 1st control group TB: * – p<0.05; ** – p<0.01; *** – p<0.001; study 
group IVDU-TB compared to the 2nd control group TB: # p<0.05; ## – p<0.01; ### – p<0.001; the 1st control group TB compared to the 2nd control group: 
● – p<0.05; ●● – p<0.01; ●●● – p<0.001;
Table 3
Distribution according to the last graduate level
Education
Study 
group
1st control 
group
2nd control 
group
N=48 (P%) N=185 (P%) N=34 (P %)
Primary &low sec-
ondary education
10 (20.8) ### 46 (24.8)●●● 22 (64.7)
Upper secondary 
education 
27 (56.2) ### 91 (49.2)●●● 1 (2.9)
Secondary technical 
vocational educa-
tion 
7 (14.6) 36 (19.5) 3 (8.8)
Bachelor studies 4 (8.3) 12 (6.5) 4 (11.7)
Note: Applied statistical test: paired simple T-test, P – probability;
Statistically significant differences between: study group IVDU-TB 
compared to the 1st control group TB: * – p<0.05;** – p<0.01; *** – p<0.001; 
study group IVDU-TB compared to the 2nd control group TB: # p<0.05; 
## – p<0.01; ### – p<0.001; the 1st control group TB compared to the 2nd 
control group: ● – p<0.05; ●● – p<0.01; ●●● – p<0.001;
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Comorbid patients statistically predominated in the SG 
and the 2rd group compared with the 1st CG. Among as-
sociated diseases, HIV infection was established in every 
second patient of the SG, which statistically predominated 
compared with the 1st CG and the 2nd CG. Chronic alco-
holism statistically predominated in the 2nd CG compared 
with the SG and the 1st CG.  Chronic respiratory diseases 
predominated in the SG and the 2nd CG. Gastro-intestinal 
disorders predominated in the 2nd CG compared with SG 
and the 2nd CG. Viral hepatitis predominated in the 2nd CG 
compared with SG and the 1st CG. Mental disorders pre-
dominated in the 2nd CG compared with the SG and the 1st 
CG. In this subgroup were not included illnesses due to the 
drug addiction. No other statistical differences were estab-
lished among groups regarding the associated diseases. Data 
were revealed in the table 4.
Studying case-management it was identified that general 
medical staff in terms of the general practitioners, was in-
volved in the detection of one half of the 1st CG and one 
third of the SG. The rate of high risk groups investigated 
through active screening was low in both groups, but the 
value was lower in the SG. Despite that drug users are a high 
risk group target by the screening procedures their propor-
tion detected by active screening was lower compared with 
the general population. Detected by the specialists as symp-
tomatic cases were in a higher proportion in the SG com-
pared with the control group, but the statistical difference 
was not achieved. Direct addressing to the specialized ser-
vices for diagnosis and treatment of tuberculosis was higher 
in the SG and demonstrated multiple barriers for accessing 
the healthcare at the primary level. Other ways of detection 
predominated in the control group and were used for diag-
nosis of patients hospitalized in somatic clinical hospitals. 
Obtained data established a lower accessibility of the health 
care services by the IVDU, due to their social vulnerabi- 
lity. The accessing of the tuberculosis specialized institu-
tions was obtained by independent addressing avoiding the 
primary health care staff in a large proportion of cases. In-
formation is exposed in the table 5.
Distributing patients according to the registered case 
type was identified that every second patient was a “new 
case” – 23 (47.9%) and every fourth was “relapse” – 12 
(25%). In a similar rate were patients included in the treat-
ment after a previous loss to follow-up and after a treatment 
failure – 6 (12.5%) patients for each category type. Diag-
nosed and transferred from abroad was 1 (2.1%) patient. 
Following the diagnosis only 46 (95.8%) patients started the 
treatment. One patient died and diagnosis was established 
after his death and one patient was transferred for treatment 
abroad (2.1% for each category type). The standard treat-
ment for new drug-susceptible tuberculosis in the RM is 
used since 2000 and lasts 6 months, according to the WHO 
recommendation [22, 42]. It consists in a two phases regi-
men with four first-line drugs: isoniazid (H), rifampicin (R), 
ethambutol (E) and pyrazinamide (Z) in the intensive phase 
and two first-line drugs: isoniazid and rifampicin in the 
continuation phase. For previously treated cases was used 
a two phase regimen which lasts 8 months: 3 months with 
H, R, E, Z and streptomycin and 5 months with H, R and E. 
Patients with rifampicin-resistant or MDR-TB were treated 
with second-line drugs for 18 months or more divided in 
two phases The regimen composition during the intensive 
phase lasts 6 months and included kanamycin (Km) or ca-
preomycin (Cm), levofloxacin (Lfx), para-amino salicylic 
acid (PAS), ethionamide (Eto), cycloserine (Cs) and pyra-
zinamide (Z) and for continuation phases during 12-18 
months of Lfx, PAS, Etho, Cs and Z. 
Identifying the clinical radiological forms of pulmonary 
tuberculosis it was established that infiltrative opacities 
were identified in a similar proportion in both groups. De-
structive forms of pulmonary tuberculosis were identified 
in a similar proportion in both groups, however the seve-
rest destructive form defined fibro-cavernous tuberculosis 
was diagnosed only in the study group. Appreciating clini-
cal radiological forms it was established that the majority of 
cases had pulmonary infiltrative tuberculosis, however sta-
tistical predominance was identified in the control group. 
Other radiological forms: disseminated tuberculosis and 
fibro-cavernous tuberculosis prevailed in the study group, 
but the statistical difference was obtained only for the fibro-
cavernous tuberculosis. Distributing patients according to 
the number of the affected lungs, it was established that 
both lungs were involved in the majority of both groups, but 
the predominantly in the study group. No differences were 
established regarding the rate of patients with parenchimal 
destruction in one or both lungs. Extensive forms, affecting 
3 and more segments were diagnosed in a similar propor-
tion in both groups (tab. 6).
When assessing the laboratory features of the enrolled 
pulmonary tuberculosis cases, it was identified that one half 
of patients were microscopic positive for acid-fast-bacilli in 
both groups. A similar proportion was identified to have 
Table 5
Case-management characteristics  
of tuberculosis patients
Health level Detection ways 
Study group
1st control 
group
N=48 (P%) N=185 (P%)
PHC Detected by GPs-
symptomatic
16 (33.3) ***
103 (55.67)
Detected by GPs-
screening of HRG
5 (10.4)
28 (15.13)
Ambulatory 
specialized 
level
Detected by SP-
symptomatics
13 (27.1)
34 (18.38)
Detected by SP-
screening of HRG
4 (8.3)
7 (3.78)
Hospital level Direct addressing 10 (20.8) ** 10 (5.41)
Others Other ways 0 3 (1.62)
Note: Applied statistical test: paired simple T-test, P – probability; GP-
general practitioner, SP-specialist, HRG-high risk group.  Statistically 
significant differences between: study group IVDU-TB compared to the 
1st control group TB: * – p<0.05;** – p<0.01; *** – p<0.001.
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positive bacteriological results (culture on solid Lowenstein-
Jensen or liquid MGIT BACTEC). The molecular genetic as-
say was performed in one half of the study group and in the 
entire control group. The differences between groups were 
determined by the period of the selection. The molecular ge-
netic test was implemented in 2014 in the RM. The sensibi-
lity to the rifampicin through GeneXpert MTB/Rif assay was 
established positive in two thirds of the control group. Drug 
sensitivity testing identified mono- and poliresistance in both 
groups in a similar proportion. In a similar proportion were 
identified patients resistant to rifampicin through Gene- 
Xpert MTB/Rif assay or conventional drug sensitivity test. 
The drug resistance was established in a similar proportion 
using the drug sensitivity testing and GeneXpert MTB/Rif 
assay in both groups. Every fifth patient from both groups 
had MDR-TB. Established data were exposed in the table 7.
All selected patients were treated according to the Na-
tional Clinical Protocol “Tuberculosis in adults”. The stan-
dard treatment for drug susceptible tuberculosis was used 
for treatment of a similar proportion of both groups: 35 
(72.9%) and 149 (80.54%) patients respectively. Every fifth 
patient from the study group was treated as previously trea-
ted cases – 9 (18.7%) patients. Even the rate of MDR-TB 
was in average similar in both groups, only a minor propor-
tion of patients from the SG started the treatment for drug 
resistant tuberculosis – 4 (8.33%) in the SG compared with 
36 (19.46%) in the CG. It is important to emphasize that 
the standard treatment for MDR-TB could be started only 
if the therapeutic compliance of the patient is established 
and the clinical tolerance is acceptable. Assessing treatment 
outcome, it was established a high statistical difference in 
the treatment success, which predominated in the control 
group 158 (85.4%) compared with 21 (43.7%) in the study 
group. The rate of patients lost to follow-up statistically pre-
dominated in the study group 10 (20.8%) compared with 2 
(1.08%) in the control group. The rate of died patients pre-
dominated in the study group 8 (16.7%) compared with 11 
(5.95%) in the control group, but the statistical difference 
was not achieve (tab. 8).
Table 8
Treatment outcome of tuberculosis patients
Index
Radiological 
features
Study group
1st control 
group
N=48 (P%) N=185 (P%)
Available final 
outcomes
Treatment success 21 (43.7) *** 158 (85.4)
Treatment failure 1 (2.1) 2 (1.08)
Loss to follow-up 10 (20.8) *** 2 (1.08)
Death 8 (16.7) 11 (5.95)
Non available 
final outcomes
Still continuing 8 (16.7) 12 (6.48)
Note: Applied statistical test: paired simple T-test, P – probability.
Statistically significant differences between: study group IVDU-TB 
compared to the 1st control group TB: * – p<0.05;** – p<0.01; *** – p<0.001.
All the patients of the 2nd CG were managed and treated 
with the standard treatment of the drug addiction according 
to the National Clinical Protocol [21]. Most of them – 26 
(76.4%) were hospitalised and treated being supported by 
the national insurance company and 8 (23.5%) – support-
ed by private costs. The methadone was used to treat the 
Table 6
Clinical forms and radiological features of tuberculosis 
patients
Index Radiological features
Study 
group
1st control 
group
N=48 (P%) N=185 (P%)
Clinical forms of 
pulmonary TB
PIT 30 (62.5) *** 170 (91.89)
PDT 7 (14.6) 15 (8.11)
FCVT 7 (14.6) *** 0
Extrapulmonary TB Bone and joints TB 3 (6.25) NA
Pleurisy 1 (2.1) NA
Localization One lung 9 (18.7) *** 80 (43.24)
Both lungs 39 (81.2) *** 105 (56.75)
Extensiveness Limited 20 (41.7) 79 (42.7)
Extensive 28 (58.3) 106 (57.3)
Radiological 
features
Infiltration 20 (41.7) 79 (42.71)
1 lung destruction 18 (37.5) 80 (43.24)
2 lungs destruc-
tion 10 (20.8) 26 (14.05)
Note: Applied statistical test: paired simple T-test, P – probability; PIT-
pulmonary infiltrative tuberculosis, PDT-pulmonary disseminated 
tuberculosis, FCVT-fibro-cavernous tuberculosis. NA-non-available; 
Statistically significant differences between: study group IVDU-TB 
compared to the 1st control group TB: * – p<0.05;** – p<0.01; *** – p<0.001.
Table 7
Microbiological features of tuberculosis patients
Microbiological characteristics
N=48 (P%)
Study group 1
st control 
group
N=185 (P%)
Mo Microscopic positive 20 (41.7) 101 (54.5)
Culture positive 24 (50) 99 (53.51)
GeneXpert performed 25 (52.1) 185 (100)
GeneXpert MTB/Rif 
positive 
13 (27.1)
185 (100)
GeneXpert MTB/Rif 
positive susceptible
4 (8.3) 147 (79.46)
GeneXpert MTB/Rif 
positive rezistent 
9 (18.7) 38 (20.54)
M0, 
M2/3
Poliresistance by DST 1 (2.1) 14 (7.56)
MDR-TB by DST 8 (16.7) 36 (19.46)
Susceptible by DST 40 (83.3) 135 (72.97)
Other 
forms
 XDR-TB 1 (2.1) 0
Note: N/A- non available; DST-Drug susceptibility testing, M0 beginning 
of the treatment, M2/3 the end of the intensive phase of the treatment; 
MDR-multidrug resistant tuberculosis, XDR-TB extensively drug-resistant 
tuberculosis; Statistical assessment was not performed due to including 
criteria in the control group.
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withdrawal syndrome 8 (23.5%) patients. Each third patient 
was treated with the standard regimen associated with other 
drugs due to disease complications. So, in 9 (26.5%) were 
associated neuroleptic drugs, in 8 (23.5%) antidepressant 
drugs and 7 (20.6%) antibiotics. Antibiotics were used for 
prevention of nosocomial infections due to subclavian ve-
nous catheter placement. The average duration of the treat-
ment during the hospitalisation was 21 days. Most of the 
IVDU 31 (91.2%) patients were therapeutically compliant 
and 3 (8.8%) were lost to follow-up. The withdrawal syn-
drome was successfully treated in 31 (91.2%) patients. No 
deaths were registered. The working capacity and perfor-
mances were restored in 29 (85.3%) cases and diminished in 
5 (14.7%) patients. The drug use consequences were identi-
fied in 28 (82.3%) patients. It is important to emphasize that 
in one patient could be several consequences and sequellae. 
So, the diminished mnestic capacities were identified in 28 
(82.3%), lack of peripheral venous access – in 20 (8.4%) and 
postinjectional signs – in 18 (52.9%) cases.
An important research outcome represents the relative 
risk (RR), odds ratio (OR) and the attributable risk (AR) 
indices for identifying the priority interventions in the 
frame of high risk groups [24,16]. In the table 8 were rep-
resented only risk factors and features which predominated 
and exposed statistical difference between the study group 
and the 2nd CG.  It was established that major risk factors 
for tuberculosis in drug addicted were: unemployment and 
associated lack of health insurance, patient’s homeless state 
and the immune suppressive condition – HIV infection and 
middle risk factors was the middle adulthood.  Attributable 
risk established the hierarchy of risks: homelessness, HIV 
infection, lack of health insurance, middle adulthood and 
unemployment (tab. 9).
The next table reflects the assessment of the disease-re-
lated features which statistically predominated in the group 
of IVDU with tuberculosis compared with patients with tu-
berculosis without drug addiction. It was established that 
major disease-related characteristic in IVDU patients is the 
severe destructive forms of tuberculosis. The major treat-
ment outcome was the “loss to follow-up”. Both lung in-
volvements were assessed as a disease-related characteristic 
with middle degree impact (tab. 10).
Conclusions
Men were predisposed for drug addiction; however, 
women frequently developed tuberculosis.
The age for acquiring tuberculosis is younger in addicted 
patients than in those without drug addiction.
Socioeconomic vulnerability is extended in the groups 
of patients with tuberculosis, with or without addiction, 
however the poverty deepness was more important in ad-
dicted patients.
Low level of education predominated in drug addicts.
Close contact with a sick patient predominated in ad-
dicted patients with tuberculosis, but nobody assessed the 
infectious contact in addicted patients without tuberculosis.
Associated diseases predominated in addicts with or 
without tuberculosis, more expressed were: HIV infected 
individuals, viral hepatitis and neurological disorders.
Risk factors for tuberculosis in drug addicted were: un-
employment and associated lack of health insurance, pa-
tient’s homeless state, middle adulthood and the immune 
suppressive condition – HIV infection.
Major disease-related characteristic in IVDU patients 
was the presence of severe destructive forms of tuberculosis 
and “loss to follow-up” as a final outcome. 
Table 9
Risk factors for tuberculosis among IVDU patients
Factors
Statistical indices
RR OR Pearson’s AR(%)
Age 35-44 years 1,56 (1,08-2,26) 3,08 (1,21-7,84) 0,01 48
Social 
economical features
Unemployment 2,59 (1,2-5,6) 6,02 (1,91-19,07) 0,0011 34
Lack of insurance 0,0015 3,22 (1,15-9,02) 0,001 54
Homelessness 1,6 (1,18-2,21) 5,67 (0,74-43,3) 0,05 100
HIV infection 2,1 (1,58-2,84) 27,10 (3,24-203,31) 4,0E-5 93
Note: RR-relative risk, OR-odds ratio; AR-attributable risk.
Table 10
Risk factors for death due to the tuberculosis progression
Factors
Statistical indices
RR OR Pearson’s AR(%)
Radiological charac-
teristics
Destructive forms of TB 1,57 (1,13-2,02) 5,63 (1,6-48,12) 0,05 100
Both lungs involvement 2,67 (1,36-5,26) 3,32(1,51-7,21) 0,001 30
Treatment outcome Loss to follow-up 4,84 (3,3-7,2) 24,08 (5,01-114,3) 0 95
Note: RR-relative risk, OR-odds ratio, AR-attributable risk, N/A-non available.
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